This one-day meeting aims at
providing the audience with a comprehensive overview and in-depth comparison of
currently available research tools, including array-, bead- or massive parallel
sequencing-based platforms as well as experimental considerations in relation
to expression-, genomic-, and epigenetic-profiling. Illustrated by real-life
examples, various internationally acknowledged speakers will provide the
attendee with critical experimental design parameters. Pitfalls associated with
specific technologies as well as their solution will be discussed extensively.
This meeting has CPD approval
9:00 – 9:45 Registration
9:45 – 10:00 Introduction by the Chair
Professor Eric F.P.M. Schoenmakers, Radboud University Nijmegen Medical Centre
(RUNMC)
& Nijmegen Centre for Molecular Life Sciences
(NCMLS), Nijmegen, The Netherlands.
10:00 – 10:30 Identification of novel biomarkers by
high-resolution copy number profiling and homozygosity mapping
in hematologic malignancies
Dr Roland P. Kuiper, Microarray Facility Nijmegen, Oncology
Research, Radboud University Nijmegen Medical Centre (RUNMC) & Nijmegen Centre for Molecular Life Sciences
(NCMLS), Nijmegen, The Netherlands
10:30
– 11:00 Comparison of MicroRNA detection platforms
Dr. Ioannis Ragoussis, Wellcome Trust Centre
for Human Genetics, University of Oxford, UK
11:00 - 11:15 Speakers
photo
11:15 – 11:45 Mid-morning break
11:45
– 12:15 Methylome analysis using array and
sequencing based approaches
Professor Stephan
Beck, Cancer Institute, University College London, UK
DNA methylation plays an essential role in biology with
wide-ranging implications for human health and disease. To understand the rules
governing DNA methylation and the consequences if DNA methylation is perturbed
requires genome-wide analysis of its temporal and spatial plasticity. Almost 60
years after the discovery of 5-methyl cytosine and about 25 years since the
discovery that altered DNA methylation plays a role in disease aetiology, particularly
in cancer, technologies have finally become available for whole-genome DNA
methylation profiling (methylome analysis) with ever increasing
resolution. I will present data from our efforts using array- and
sequencing-based platforms for high-throughput DNA methylation analysis,
discuss some of the lessons learnt and give an outlook on how the data may be
used in an integrated approach – termed ‘reverse phenotyping’ – to
analyse and better understand the (epi)genomics of phenotypic plasticity in
health and disease.
12:15 – 12:45 Selected
Abstracts
12:45 – 13:00 Brief introduction to the
Biopark
14:00
– 14:30 Talk to be confirmed
14:30 – 15:00 A comparison of expression profiling
by deep sequencing and microarrays
Dr. Peter A.C. ‘t Hoen, Center for
Human and Clinical Genetics, Leiden University Medical Center (LUMC),
Leiden, The Netherlands
15:00 – 15:30 Afternoon Tea/Coffee and Last Poster
Viewing
15:30 - 16:00 Use of new sequencing technologies
for the annotation of cancer genomes
Dr. Peter J. Campbell, Sanger Institute,
Cambridge, UK
We are now entering an era in which it will be
feasible to catalogue every genetic event in a cancer. Next generation
sequencing platforms already offer the capacity to generate gigabases (Gb) of
sequence each week at a cost of less than 1 cent per kilobase (kb). Techniques
have been developed which allow the detection of genomic rearrangements, copy
number changes, point mutations and small insertions and deletions as well as
epigenetic alterations on a single instrument. This will be a significant
advance on existing approaches to cancer genomics. The analysis will be
genuinely genome-wide, cataloguing genetic changes not only in coding sequence
but also the other 98% of the human genome including, for example, promoters,
enhancers and non-coding RNAs. At the Cancer Genome Project, we have developed
protocols for mapping acquired rearrangements to the base-pair level, providing
insights into the diversity of aberrant processes sculpting the genome which
underlie the evolution and development of cancer.
16:00 – 16:30 Selected Abstracts
18:00 Soiree at *The Best Western Homestead Court
Hotel* for all the participants
This meeting was organised by
Euroscicon (www.euroscicon.com), a team of dedicated
professionals working for the continuous improvement of technical knowledge
transfer to all scientists. Euroscicon believe that they can make a positive
difference to the quality of science by providing cutting edge information on
new technological advancements to the scientific community. This is
provided via our exceptional services to individual scientists, research
institutions and industry. The event was hosted by 'BioPark (www.biopark.co.uk), a research and development centre in
Welwyn Garden City providing specialist facilities and support for bioscience and
health technology businesses to grow, and to develop new products and
technologies
*To book your accommodation at BEST WESTERN HOMESTEAD COURT HOTEL and any travel
arrangements please download the booking form or contact
us with your requirements to accommodationandtravel@euroscicon.com /
+ 44 (0) 1926 888027. We will negotiate the best rates for you
About the chair
Professor Eric F.P.M. Schoenmakers, Radboud University Nijmegen Medical
Centre (RUNMC) & Nijmegen
Centre for Molecular Life Sciences (NCMLS), The Netherlands. Eric Schoenmakers obtained his PhD in Medical
Sciences (Molecular Oncology) from the University of Leuven in Belgium (1997),
where he studied the molecular basis of benign mesenchymal solid tumor
development, and identified HMGA2 as the most frequently targeted
oncogene in humans (Schoenmakers et al., Nature Genetics 1995). In 2000 he was appointed assistant professor
and scientific board member at the department of Human Genetics at the
University of Nijmegen, The Netherlands, where he is currently studying the
genetic basis of cancer and (other) genetic diseases using high-throughput
molecular cytogenetic approaches including array-based comparative genomic
hybridisation (CGH). His main research-focus is on brain and urogenital
cancers, including kidney cancer and gynecological neoplasms. In 2004 he was
appointed Strategic Advisor to the Scientific Director. He is currently the
chairman of the Dutch Cancer Society for Tumor Cell Biology, member of several
international review boards, and has (co-) authored over 100 international
peer-reviewed scientific publications. In
addition, Eric is a full-blown “Tango Argentino” addict, and never travels
without his “zapatos para bailar”.
About the Speakers
Dr. Roland Kuiper studied Biology in Nijmegen where he
graduated in 1994. He performed a PhD at the department of Animal Physiology in
Nijmegen (prof. dr G. Martens) on selective intracellular prohormone transport
in endocrine cells. In 2001, he joined the department of Human Genetics for a
post-doc, where he focused on the characterization of renal cell carcinomas carrying
t(6;11)(p21;q11) chromosomal translocations. Since 2005, he heads the tumor
cell genetics group within the microarray facility at the department of Human
Genetics, Nijmegen. His research focuses on genomic aberrations in hereditary
kidney and colon cancers, head and neck cancers, childhood cancers and
hematologic malignancies
Professor Stephan
Beck is
Professor of Medical Genomics at the University College London Cancer Institute.
His laboratory has broad interests in the genomics and epigenomics of
phenotypic plasticity in health and disease. He received his PhD in 1985 from
the University of Konstanz where he studied DNA structure. After appointments
at the MRC Laboratory of Molecular Biology in Cambridge, Millipore Corporation
in Boston and the Imperial Cancer Research Fund in London, he joined the Sanger
Institute in 1996. During his tenure as Head of Human Sequencing (1998-2006),
he contributed to the sequencing and analysis of the human, mouse and zebrafish
genomes.
Dr Peter
Campbell’s primary research interest is in cancer
genomics. In the last two years, based at the Cancer Genome Project at the
Sanger Institute, he has concentrated on the application of new sequencing
technologies to the annotation of cancer genomes